NCT07337967Not yet recruiting
Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative Neoplasms
Source: ClinicalTrials.gov · Last updated 13 Jan 2026
Brief summary (registry, in English)
Reticulocyte parameters as early indicators of bone marrow erythropoietic activity in chronic B lymphoproliferative neoplasms
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 13 Dec 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 1 Feb 2027
- Lead sponsor
- Huda Ahmed Abdelsabour Abdelwahab
- Diseases
- Chronic lymphocytic leukaemia
- NCT number
- NCT07337967
What you commit to
- Study type: Observational
- Planned participants: 120
- From 1 Jan 2026 to the primary completion date, 1 Feb 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1\) Patients received chemotherapy.
- Patients on haematinics or vitamin B 12 therapy
Other illness
- Patients with Active bleeding
Other
- Patients with recent blood transfusion (less than 2 weeks).
Who the study is looking for
- \- Newly diagnosed adult patients with Chronic B LymphoPoliferative neoplasm according to WHO classification.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.